KM Research Hub
← 返回论文库
待处理 入排:排除 图源:待检查

Quadruplet therapy for newly diagnosed myeloma: comparative analysis of sequential cohorts with triplet therapy lenalidomide, bortezomib and dexamethasone (RVd) versus daratumamab with RVD (DRVd) in transplant-eligible patients.

Nisha S Joseph, Jonathan L Kaufman, Vilas A Gupta, Craig C Hofmeister, Madhav V Dhodapkar, Lawrence H Boise, Sara M DiCamillo, Danielle Roberts, Ajay K Nooka, Sagar Lonial

Blood Cancer J 14(1) 159

PMID39271684
PMCIDPMC11399152
DOI10.1038/s41408-024-01120-9
发表日期2024-09-13
摘要

摘要

Lenalidomide, bortezomib, and dexamethasone (RVd) have previously been established as standard-of-care induction therapy for newly diagnosed multiple myeloma (NDMM). More recently, randomized phase 3 data have demonstrated the benefit of the addition of daratumumab (Dara-RVd) to the RVd backbone in terms of improved both depth of response and long-term survival benefit as measured by progression-free survival (PFS). Our group has previously published on a historical cohort of 1000 NDMM patients uniformly treated with RVd induction with impressive both PFS and overall survival. Here, we present a comparative analysis of our RVd cohort with a recent cohort of 326 patients induced with Dara-RVd at our institution with intent to transplant. This analysis demonstrates the utility of this regimen in real-world clinical practice and provides additional insights into D-RVd performance in patient subsets often underrepresented in clinical trials, as well as the impact of daratumumab in maintenance for NDMM patients.

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。